title: Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
abstract: Several matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been implicated in the development and outcome of coronary artery disease (CAD). We investigated whether MMP-12 and TIMP-1 levels were associated with risk, severity, and outcome of CAD. Plasma MMP-12 and TIMP-1 levels are measured in 50 and 44 patients with CAD, respectively, by enzyme-linked immunosorbent assay. Of all patients, 16 were taking statins. Patients who were not on statins were classified into 3 groups according to number of >50% stenotic vessels. Compared with 29 volunteers without CAD, patients without statins (n = 34) had higher MMP-12 concentrations (1.71 vs 1.08 ng/ml, p = 0.021). MMP-12 levels were significantly lower in patients with than in those without statin treatment (0.99 vs 1.71 ng/ml, p = 0.008). There was no association between MMP-12 levels and number of >50% stenotic vessels. MMP-12 concentrations were not associated with outcome of CAD. However, plasma TIMP-1 levels were associated with restenosis independently of number of stenotic vessels and age (p = 0.035) but not with risk or severity of CAD. In conclusion, plasma MMP-12 concentration was associated with the presence of CAD. Statin therapy decreases plasma MMP-12 levels in patients with CAD. Increased TIMP-1 levels may prevent restenosis after angioplasty.
authors.affiliation: Unit of Research, Genetic and Biologic Factors of Atherosclerosis, Faculty of Medicine, CHU Fattouma, Bourguiba, Monastir, Tunisia.
authors.forename: Imen
authors.initials: I
authors.lastname: Jguirim-Souissi
authors.forename: Awatef
authors.initials: A
authors.lastname: Jelassi
authors.forename: Faouzi
authors.initials: F
authors.lastname: Addad
authors.forename: Majed
authors.initials: M
authors.lastname: Hassine
authors.forename: Mohamed
authors.initials: M
authors.lastname: Najah
authors.forename: Khaldoun
authors.initials: K
authors.lastname: Ben Hamda
authors.forename: Faouzi
authors.initials: F
authors.lastname: Maatouk
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ben Farhat
authors.forename: Ali
authors.initials: A
authors.lastname: Bouslema
authors.forename: Mustapha
authors.initials: M
authors.lastname: Rouis
authors.forename: Mohamed Naceur
authors.initials: MN
authors.lastname: Slimane
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D053508:Matrix Metalloproteinase 12 / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D053508:Matrix Metalloproteinase 12